|Bid||18.16 x 1000|
|Ask||18.48 x 800|
|Day's range||18.30 - 18.44|
|52-week range||11.48 - 19.50|
|Beta (5Y monthly)||1.57|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.00|
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Cellular Biomedicine Group, Inc. ("CBMG" or the "Company") (NasdaqGS: CBMG) to a newly-formed entity consisting of CBMG’s CEO Tony Liu, certain member of the Company's management, and a consortium of stockholders and equity investors. Under the terms of the proposed transaction, shareholders of CBMG will receive only $19.75 in cash for each share of CBMG they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Rowley Law PLLC is investigating potential securities law violations by Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) and its board of directors concerning the proposed acquisition of the company by members of Cellular Biomedicine Group’s senior management and other investors. Stockholders will receive $19.75 in cash for each share of Cellular Biomedicine Group stock that they hold. The transaction is expected to close in the fourth quarter of 2020.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by a consortium led by Cellular Biomedicine’s CEO Bizuo Liu ("the Consortium").